Seeing advantage as a European leader in eye health

About VISUfarma

VISUfarma is pan-European ophthalmic specialty pharmaceutical company with a clear mission; to bring global innovation to European eye health. We are an ambitious and fast growing ophthalmology player, commercialising a wide portfolio of products and devices across Europe. Our promise is to offer high quality products and to spread eye health innovation and knowledge, from across the globe, throughout Europe.

European platform, global network

Our platform is underpinned by the acquisition of the international commercial operations of Nicox SA (France) and Visufarma SpA (Italy) and will be further enhanced through strategic partnerships with global partners. VISUfarma fosters a unique network in the ophthalmology space which enables physicians, hospitals and medical centres to provide patients with the highest quality eye care.

VISUfarma was founded in 2016 and has a strong presence in five European countries: France, Germany, Italy, Spain and the United Kingdom. The company has more than 150 employees and its head office is based in Amsterdam, the Netherlands.

“Our promise is to offer high quality products and to spread eye health innovation and knowledge”

Management

Tom J. van Haarlem, MD

Chief Executive Officer

Tom J. van Haarlem, MD

Chief Executive Officer

Tom has over 25 years of experience as an executive in various commercial, strategic and R&D leadership positions at global pharmaceutical companies in Europe and in the USA, where he lived most of his career. Prior to joining VISUfarma as Chief Executive Officer in 2016, Tom was President of Novaer in New Jersey (USA), which he founded in 2012 to develop a sustained drug delivery implant for glaucoma treatment.

In 2005, Tom founded Aerie Pharmaceuticals and was the company’s President and CEO through its subsequent IPO in 2013, having raised $74 million of venture capital funding since its inception. During that time, he built the company in New Jersey (USA) with R&D capabilities in North Carolina (USA), and led the successful discovery and development of a proprietary pharmaceutical products portfolio with a novel MOA for the treatment of glaucoma, now in late Phase III development.

At Pfizer, he managed the successful divestiture of the surgical ophthalmology franchise as VP of Global Operations. Before that, at Pharmacia, he was Vice-President leading commercial development of the specialty care portfolio, including ophthalmology products such as billion-dollar glaucoma blockbuster Xalatan. Tom led European marketing of cardiovascular products at Merck as part of a multi-billion franchise, achieving several years annual double-digit growth. Aside from his executive roles, Tom is also an experienced private investor, board director and advisor to venture capital and private equity firms. Tom qualified as a medical doctor at the University of Amsterdam and continued his business education at the NIMA Institute. A native Dutch speaker, Tom is fluent in English and German and is conversational in French.

Björn Hermes

Chief Financial Officer

Björn Hermes

Chief Financial Officer

Björn has over 12 years of experience across the globe as an executive in various commercial, strategic and financial positions at Lafarge and at Merck. At Lafarge, he managed a review of the German production sites and organizational restructuring, which improved financial health.

At Merck he has held positions in Commercial & Subsidiary Controlling and Technical Operations during various transforming acquisitions and was CFO and member of the Board for the affiliates of Merck in the Middle-East region and for the Netherlands and Belgium. In the Middle-East, he managed establishing SAP R/3 and contract manufacturing activities, enabling the business to more than double organically in two years. In his recent role in the Netherlands and Belgium, he led a transformation of the business from Finance resulting in a growth against the market trend. Furthermore, Björn was managing the Holding activities of Merck in the Netherlands and supported its multi-billion dollar global participations during the acquisition of Sigma-Aldrich, and included mergers, valuations, taxation, and financing.

Within the broad field of Finance, Björn’s has a strong business orientation through financial transparency and ownership, process development and pragmatic problem solving. Björn holds a Master (Diplom Kaufmann) degree in Economics and International Management from the Otto-von-Guericke University in Magdeburg. A native German speaker, Björn is fluent in English.

Ingrid A.M. Jutte

VP Human Resources

Ingrid A.M. Jutte

VP Human Resources

Ingrid is a Human Resources executive with over 15 years of experience in complex, multinational environments responsible for various organisational levels and multiple functional areas. During her career, Ingrid has held positions in Human Resources, Marketing & Sales, Acquisitions & Divestments and was Company Secretary during times of strategic change.

Ingrid is highly experienced executive in international organisations. She has led large global virtual teams and has been involved in acquisition and divestment projects around the world, resulting in extensive project and change management expertise. Within the broad field of Human Resources, Ingrid’s key strengths lie in employee relations, organisational development, HR capability building and leadership development.
Most recently, Ingrid was Global HR Partner of AkzoNobel’s CFO and his direct reports. Headquartered in Amsterdam, AkzoNobel is a €15 billion multinational company with 45,000 employees in the field of specialty chemicals, paints and coatings. In this role Ingrid provided HR leadership, expertise including organisational design, talent management, remuneration, engagement, education & training, and partnership to the global Finance and Information Management functions with approximately 3,500 employees.

Ingrid holds a master degree in Business Administration from the Rotterdam School of Management. A native Dutch speaker, Ingrid is fluent in English and German and is conversational in Swedish.

Raquel Ramkisoen MSc MBA

Vice President Quality, Regulatory Affairs & Vigilance

Raquel Ramkisoen MSc MBA

Vice President Quality, Regulatory Affairs & Vigilance

Raquel has broad experience in regulatory affairs, quality, pharmacovigilance, market access and business development. Before joining VISUfarma she spent eleven years at Sanofi as Regulatory Affairs Manager and was Qualified Person and Deputy Country Quality Head. She then changed to Business Development for the Benelux organization and was responsible for the diversification of the product portfolio by identifying and analyzing targets for acquisition and for in‐and out‐licensing deals. Subsequently, she changed position to become Attaché to the General Manager Benelux where she led strategic projects and gained experience in P&L, budget and business reviews. Then she moved to Market Access and since April 2014 Raquel was Country Head QRV for Sanofi in the Netherlands.

Before joining Sanofi Raquel worked at the Medicines Evaluation Board and Hexal, a generic pharmaceutical company.

Raquel holds a Master degree in Biopharmaceutical Sciences from the University of Leiden (NL) as well as an MBA from NCOI and a post-graduate degree in Health Economics from EHSAL Management School in Brussels.

Keren Leshem

Vice-President Corporate Development

Keren Leshem

Vice-President Corporate Development

Keren has been CEO of ViSci (Vision Sciences) Ltd since 2011, where she has successfully led R&D and Business Development. Her expertise lies in the field of ophthalmic pharmaceuticals and medtech innovation. In addition to her position at ViSci, Keren has worked for several pharmaceutical companies and she was a business development consultant to several start-ups in the biotech and medtech fields.

Prior to these positions in the biomedical space, Keren was an EVP of Marketing & Sales at an Israeli-based commercial organization where she was responsible for managing and expanding a global network of over 80 distributors across the globe.

Keren is a lieutenant in the Israeli army. She studied 2 years of pre-med at Maryland University in the USA, and completed her undergraduate education in Business from New England University. She also holds a marketing MBA from Clark University, USA.

Previous  

Partners

GHO Capital

Global Healthcare Opportunities (GHO Capital) is a specialist healthcare investment adviser based in London. GHO Capital Fund I LP is the majority investor in VISUfarma.

Nicox

Nicox is an international ophthalmic R&D company and is a minority investor in VISUfarma.

Partner with Us

Enquiry form

Is there anything we can help you with? From requesting a product sample, arranging a visit from one of our helpful customer representatives, or simply asking us a question about VISUfarma products. Use the form and we’ll be in touch as soon as possible.

Fields indicated with * are required

Thank you for your enquiry!

Choose country website



By clicking “Go” you are agreeing to leave the global VISUfarma website
and be directed to a regional website.